Functional Involvement of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in the Renal Elimination of the Antiviral Drugs Adefovir and Tenofovir

Acyclic nucleotide phosphonates (adefovir, cidofovir, and tenofovir) are eliminated predominantly into the urine, and renal failure is their dose-limiting toxicity, particularly for adefovir and cidofovir. In this study, we examined the involvement of multidrug resistance-associated protein (MRP)4 (ABCC4) in their luminal efflux in the kidney. ATP-dependent uptake of adefovir and tenofovir but not cidofovir was observed only in the membrane vesicles expressing MRP4. The ATP-dependent uptake of adefovir and tenofovir by MRP4 was not saturated at 1 mM. The ATP-dependent uptake of adefovir by membrane vesicles expressing MRP4 was osmotic-sensitive. No ATP-dependent uptake of either agent was observed in the membrane vesicles expressing human MRP2 or breast cancer resistance protein. These nucleotide analogs were given to mice by constant intravenous infusion, and the plasma, urine, and tissue concentrations were determined. The kidney accumulation of adefovir and tenofovir was significantly greater in Mrp4 knockout mice (130 versus 66 and 191 versus 87 pmol/g tissue, respectively); thus, the renal luminal efflux clearance was estimated to be 37 and 46%, respectively, of the control. There was no difference in the fraction of mono- and diphosphorylated forms of adefovir in the kidney between wild-type and Mrp4 knockout mice. In mice, cidofovir was also eliminated via the urine by tubular secretion as well as glomerular filtration. There was no change in the kinetic parameters of cidofovir in Mrp4 knockout mice. Our results suggest that MRP4 is involved in the luminal efflux of both adefovir and tenofovir, but it makes only a limited contribution to the urinary excretion of cidofovir.

[1]  M. Kool,et al.  Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. , 1997, Cancer research.

[2]  J. Schuetz,et al.  MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs , 1999, Nature Medicine.

[3]  J. C. Martin,et al.  Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. , 1992, Molecular pharmacology.

[4]  Richard D Moore,et al.  Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  M. Connelly,et al.  Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells , 1995, Antimicrobial agents and chemotherapy.

[6]  T. Cihlar,et al.  Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. , 2000, Journal of the American Society of Nephrology : JASN.

[7]  T. Cihlar,et al.  The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. , 1999, Molecular pharmacology.

[8]  H. Izzedine,et al.  Renal tubular transporters and antiviral drugs: an update , 2005, AIDS.

[9]  H. Koepsell,et al.  The SLC22 drug transporter family , 2004, Pflügers Archiv.

[10]  William A. Lee,et al.  NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, 20(4–7), 1091–1098 (2001) METABOLISM OF GS-7340, A NOVEL PHENYL MONOPHOSPHORAMIDATE INTRACELLULAR PRODRUG OF PMPA, IN BLOOD , 2003 .

[11]  E. De Clercq,et al.  Pharmacokinetics in mice of the anti-retrovirus agent 9-(2-phosphonylmethoxyethyl)adenine. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[12]  S. Wright.  Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics. , 2005, Toxicology and applied pharmacology.

[13]  D. H. Sweet.  Organic anion transporter (Slc22a) family members as mediators of toxicity. , 2005, Toxicology and applied pharmacology.

[14]  M. Bray,et al.  Aerosolized Cidofovir Is Retained in the Respiratory Tract and Protects Mice against Intranasal Cowpox Virus Challenge , 2003, Antimicrobial Agents and Chemotherapy.

[15]  Y. Sugiyama,et al.  Characterization of the Cellular Localization, Expression Level, and Function of SNP Variants of MRP2/ABCC2 , 2004, Pharmaceutical Research.

[16]  E. De Clercq,et al.  Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Wulfsohn,et al.  Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. , 1999, JAMA.

[18]  E. De Clercq.  Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections , 2003, Clinical Microbiology Reviews.

[19]  D. Keppler,et al.  Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane , 2003, Hepatology.

[20]  E. De Clercq,et al.  5-Phosphoribosyl 1-pyrophosphate synthetase converts the acyclic nucleoside phosphonates 9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxyethyl)adenine directly to their antivirally active diphosphate derivatives. , 1991, The Journal of biological chemistry.

[21]  Xingguo Cheng,et al.  TISSUE DISTRIBUTION AND HEPATIC AND RENAL ONTOGENY OF THE MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN (MRP) FAMILY IN MICE , 2005, Drug Metabolism and Disposition.

[22]  T. Cihlar,et al.  Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. , 2000, The Journal of pharmacology and experimental therapeutics.

[23]  Wooin Lee,et al.  Transporters and renal drug elimination. , 2004, Annual review of pharmacology and toxicology.

[24]  Y. Sugiyama,et al.  Functional Analysis of SNPs Variants of BCRP/ABCG2 , 2004, Pharmaceutical Research.

[25]  F. Russel,et al.  The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. , 2002, Journal of the American Society of Nephrology : JASN.

[26]  J. Wijnholds,et al.  Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. , 2003, Molecular pharmacology.

[27]  H. Endou,et al.  Molecular physiology of renal organic anion transporters. , 2006, American journal of physiology. Renal physiology.

[28]  P. Wielinga,et al.  Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). , 2003, The Biochemical journal.

[29]  S. Masuda,et al.  Cellular and molecular aspects of drug transport in the kidney. , 2000, Kidney international.

[30]  T. Cihlar,et al.  NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, 20(4–7), 641–648 (2001) HUMAN RENAL ORGANIC ANION TRANSPORTER 1 (hOAT1) AND ITS ROLE IN THE NEPHROTOXICITY OF ANTIVIRAL NUCLEOTIDE ANALOGS , 2003 .

[31]  K. Cundy.  Clinical Pharmacokinetics of the Antiviral Nucleotide Analogues Cidofovir and Adefovir , 1999, Clinical pharmacokinetics.

[32]  H. Denk,et al.  Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[33]  H. Rosing,et al.  The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  F. Goebel,et al.  HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  F. Russel,et al.  Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. , 2005, American journal of physiology. Renal physiology.

[36]  D. Keppler,et al.  Expression of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney proximal tubules. , 1997, Journal of the American Society of Nephrology : JASN.

[37]  R. Evans,et al.  Interactions between Hepatic Mrp4 and Sult2a as Revealed by the Constitutive Androstane Receptor and Mrp4 Knockout Mice* , 2004, Journal of Biological Chemistry.

[38]  B. Kuppermann,et al.  Intravenous Cidofovir for Peripheral Cytomegalovirus Retinitis in Patients with AIDS , 1997, Annals of Internal Medicine.

[39]  P. Wielinga,et al.  Mrp4 Confers Resistance to Topotecan and Protects the Brain from Chemotherapy , 2004, Molecular and Cellular Biology.

[40]  M. Nishimura,et al.  Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. , 2005, Drug metabolism and pharmacokinetics.